StoxCaplin Point Laboratories vs NATCO Pharma: share price & financials comparison
NSE: CAPLIPOINT vs NATCOPHARM · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Caplin Point Laboratories vs NATCO Pharma at a glance
Caplin Point Laboratories (CAPLIPOINT) has a market capitalisation of ₹18,154 Cr, against ₹14,507 Cr for NATCO Pharma (NATCOPHARM). Over the past year Caplin Point Laboratories has returned +19.7%, compared with -1.1% for NATCO Pharma. On valuation, NATCO Pharma trades at a lower P/E of 17.5 versus 26.3. Caplin Point Laboratories earns a higher return on equity (17.7% vs 8.5%). Caplin Point Laboratories comes out ahead on profitability, growth, financial health, momentum and technicals. NATCO Pharma comes out ahead on size and valuation. Across the scored metrics below, Caplin Point Laboratories leads on 13 and NATCO Pharma on 5. On StoxGud's 10-point checklist, Caplin Point Laboratories scores 9/10 and NATCO Pharma scores 5/10.
| Metric | Caplin Point Laboratories | NATCO Pharma |
|---|---|---|
| Size | ||
| Market cap | ₹18,154 Cr | ₹14,507 Cr |
| Revenue (latest FY) | ₹2,187 Cr | ₹4,078 Cr |
| Net profit (latest FY) | ₹641 Cr | ₹1,418 Cr |
| Valuation | ||
| P/E | 26.3 | 17.5 |
| P/B | 4.65 | 1.49 |
| Dividend yield | 0.25% | 0.62% |
| Profitability | ||
| Return on equity | 17.7% | 8.5% |
| Net profit margin | 28.9% | 26.8% |
| Operating margin | 34.9% | 23.7% |
| Growth | ||
| Revenue growth (YoY) | +17.9% | -29.0% |
| Net profit growth (YoY) | +15.3% | -60.9% |
| Revenue CAGR (multi-year) | +15.6% | +14.7% |
| Financial health | ||
| Debt to equity | 0.00 | 0.11 |
| Momentum | ||
| 1-month return | +1.1% | +2.7% |
| 1-year return | +19.7% | -1.1% |
| 3-year CAGR | +23.7% | +0.7% |
| 5-year CAGR | +22.7% | -0.9% |
| 10-year CAGR | +21.3% | +2.2% |
| Distance from 52W high | -16.7% | -32.8% |
| Technicals | ||
| RSI (14) | 64 | 65 |
| Price vs 200-day avg | +9.1% | -12.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Caplin Point Laboratories | NATCO Pharma |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 9/10 | 5/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Caplin Point Laboratories or NATCO Pharma?
Caplin Point Laboratories has a market cap of ₹18,154 Cr and NATCO Pharma has a market cap of ₹14,507 Cr as of 13 Nov 2026.
Which has a lower P/E, Caplin Point Laboratories or NATCO Pharma?
NATCO Pharma has the lower P/E: Caplin Point Laboratories trades at 26.3 and NATCO Pharma at 17.5.
Which gave better returns in the last year, Caplin Point Laboratories or NATCO Pharma?
Caplin Point Laboratories did better: Caplin Point Laboratories returned +19.7% and NATCO Pharma returned -1.1% over one year.
What is the difference between Caplin Point Laboratories and NATCO Pharma?
Both are NSE-listed companies in Healthcare. Caplin Point Laboratories is about 1.3 times the size of NATCO Pharma by market cap. In the latest financial year Caplin Point Laboratories reported revenue of ₹2,187 Cr and NATCO Pharma ₹4,078 Cr. Operating margin is 34.9% for Caplin Point Laboratories and 23.7% for NATCO Pharma. Debt to equity is 0.00 for Caplin Point Laboratories and 0.11 for NATCO Pharma.
Which is better, Caplin Point Laboratories or NATCO Pharma?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Caplin Point Laboratories leads on 13 and NATCO Pharma on 5. Caplin Point Laboratories is ahead on profitability, growth, financial health, momentum and technicals. NATCO Pharma is ahead on size and valuation. On StoxGud's rules-based checklist Caplin Point Laboratories scores 9/10 and NATCO Pharma scores 5/10. This is information, not advice: consult a SEBI-registered adviser before investing.